Genomtec S.A.

Warsaw Stock Exchange GMT.WA

Genomtec S.A. Cash and Short-Term Investments for the year ending December 31, 2023: USD 1.06 M

Genomtec S.A. Cash and Short-Term Investments is USD 1.06 M for the year ending December 31, 2023, a 11.91% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Genomtec S.A. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 944.69 K, a 176.12% change year over year.
  • Genomtec S.A. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 342.13 K, a -82.50% change year over year.
  • Genomtec S.A. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 1.95 M, a 422.03% change year over year.
  • Genomtec S.A. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 374.44 K.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
Warsaw Stock Exchange: GMT.WA

Genomtec S.A.

CEO Mr. Miron Tokarski Ph.D.
IPO Date March 17, 2021
Location Poland
Headquarters Bierutowska Street 57-59
Employees 17
Sector Healthcare
Industries
Biotechnology Medical Instruments
Description

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.

StockViz Staff

February 8, 2025

Any question? Send us an email